Navigation Links
Insmed Incorporated Announces Lifting of Clinical Hold by U.S. Food and Drug Administration on ARIKACE® in Cystic Fibrosis Patients With Pseudomonas Lung Infections
Date:5/7/2012

MONMOUTH JUNCTION, N.J., May 7, 2012 /PRNewswire/ -- Insmed Incorporated (Nasdaq CM: INSM), a biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has lifted the clinical hold previously placed on ARIKACE® (liposomal amikacin for inhalation) in Cystic Fibrosis (CF) patients with Pseudomonas lung infections.

Insmed has reached agreement with FDA on a revised CF clinical trial population consisting of adult patients who have chronic Pseudomonas lung infections and FEV-1 % predicted between 25% and 75%.  The Company is continuing discussions with the Agency in an effort to finalize additional details of the phase 3 study protocol for the potential clinical trial.  At the same time, the Company is evaluating possible next steps for the ARIKACE U.S. CF clinical program given the current progress and anticipated resource requirements of the ongoing ARIKACE CF (CLEAR-108) and U.S. non-tuberculous mycobacteria (NTM) clinical programs.

"We are pleased that FDA has lifted the clinical hold on the ARIKACE studies in both CF and, as previously disclosed, in patients with NTM lung disease," said Timothy Whitten, President and CEO of Insmed.  "We believe that ARIKACE has the potential to be an important treatment option for CF patients who have Pseudomonas lung infections, and patients who have lung infections due to NTM."

As recently announced, Insmed has begun dosing patients in CLEAR-108, a European and Canadian registrational phase 3 clinical study of ARIKACE in CF patients, and is proceeding with CLEAR-110, a follow-on multi-cycle open-label study intended primarily to measure safety and tolerability for patients who complete CLEAR-108.  The Company also previously announced it is initiating a U.S. phase 2 clinical trial of ARIKACE in NTM. 

About Insmed

Insmed Incorporated is a biopharmaceutical company focused on the developm
'/>"/>

SOURCE Insmed Incorporated
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Insmed to Host 2012 First Quarter Earnings Conference Call
2. Insmed to Host Fourth Quarter and 2011 Year-End Earnings Conference Call
3. Insmed to Present at Lazard Capital Markets 8th Annual Healthcare Conference
4. Insmed Incorporated Provides Regulatory Update on ARIKACE® in Non-Tuberculous Mycobacteria Indication
5. Insmed Incorporated Provides Regulatory Update
6. Insmed to Present at Sixth Annual JMP Securities Healthcare Conference
7. Insmed Announces Financial Results for Second Quarter and Six-Months Ended June 30, 2011
8. Insmeds ARIKACE® Demonstrates Sustained Benefit Through Six Cycles of Treatment for Cystic Fibrosis Patients With Pseudomonas Lung Infections
9. Insmed Announces First Quarter 2011 Financial Results
10. Insmed to Host 2011 First Quarter Earnings Conference Call
11. Insmed Announces European Medicines Agency Acceptance of Its Pediatric Investigation Plan for ARIKACE™ in the Cystic Fibrosis Pseudomonas Indication
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... NORTHBROOK, Ill. , July 31, 2014 /PRNewswire/ ... as the head of corporate and employee communications ... to Jeff Winton , senior vice president, ... be responsible for developing and leading corporate brand ... business goals across North and South ...
(Date:7/31/2014)... SPRINGFIELD, Ill. , July 31, 2014 /PRNewswire/ ... (LRS) announced a new extension to its PageCenterX ... software is designed to provide downtime ... unplanned system outages. LRS is releasing the product ... the healthcare environment, EMR applications experience outages for ...
(Date:7/31/2014)... July 31, 2014 Orexigen® Therapeutics, Inc. (Nasdaq: ... the second quarter 2014, on Thursday, August 7, 2014 ... a live webcast and conference call at 8:00 a.m. ... management will host the call and webcast to discuss ... may be accessed by calling (800) 708-4540 (domestic) or ...
Breaking Medicine Technology:Astellas Hires Industry Veteran Moyra Knight as Head of Corporate and Employee Communications 2LRS Announces Downtime Reporting Solution for Healthcare 2Orexigen Therapeutics to Host Second Quarter 2014 Financial Results Conference Call and Webcast 2
... - Planning for Phase 3 Trial Initiation on ... Progen,Pharmaceuticals Limited (ASX: PGL; Nasdaq: PGLA) today announced ... largest Contract Research,Organisation, to utilise their services for ... includes the execution of the,Phase 3 clinical trial ...
... Presentations on the Topic of Drug Repurposing and ... Indian Clinical ... Inc., an,oncology-focused, clinical-stage biopharmaceutical company, announced today,that Chief Executive Officer, ... present at the 234th American Chemical,Society National Meeting on Sunday, ...
Cached Medicine Technology:Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88 2Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88 3Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA 2Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA 3
(Date:7/31/2014)... Ticket Down is a reputable source for ... Santa Clara, California. Fans in the United States of international soccer ... club and national teams in the world. Coming off the heels ... the best time to be a fan of soccer in the ... on American soil this year, as well as international friendly games ...
(Date:7/31/2014)... 2014 David Kekich, anti-aging icon ... ) is thrilled that the acceptance of his ... Artificial Intelligence (AI) algorithms and then screening thousands ... acceptance. , “It took longer than ... proof is in," said Kekich. "Client acceptance is ...
(Date:7/31/2014)... 2014 Much of the liver,s metabolic function is ... and UC Irvine researchers have now found two ... published online today in Cell , reveals new ... points the way to more focused drug treatments for ... diabetes. , Paolo Sassone-Corsi, UCI,s Donald Bren Professor of ...
(Date:7/31/2014)... New York, NY (PRWEB) July 31, 2014 ... business-to-business publication dedicated to delivering cutting-edge information ... biopharmaceuticals and therapeutics, recently launched its newly ... new website optimizes navigation by providing visitors ... manufacturing, analytical and strategic business areas. As ...
(Date:7/31/2014)... teens never outgrow their "growing pains," according to new ... affecting teens, participation in sports and other activities, a ... can become chronic, the researchers cautioned. "We can ... people between the ages of 12 and 19 experience ... Rathleff, a physiotherapist from Aarhus University. "Seven percent of ...
Breaking Medicine News(10 mins):Health News:Mexico vs. Chile Tickets Levi’s Stadium: Ticket Down Slashes Ticket Prices for Chile vs. Mexico at Levi’s Stadium in Santa Clara, California on September 6th 2Health News:Mexico vs. Chile Tickets Levi’s Stadium: Ticket Down Slashes Ticket Prices for Chile vs. Mexico at Levi’s Stadium in Santa Clara, California on September 6th 3Health News:MaxLife Solution™ Expands Distribution Globally for Breakthrough Anti-Inflammatory Support Supplement – InflaGene™ 2Health News:Strict genomic partitioning by biological clock separates key metabolic functions 2Health News:BioProcess International Launches New Website 2Health News:Teen 'Growing Pains' May Persist For Years 2
... , CLEVELAND, Aug. 12 The Sisters of Charity ... its legal department. Jerse will serve as General Counsel to St. ... Counsel for the health system. , , "We ... expertise that Shannon brings to this new position," says Sister Judith ...
... patients, survey found , WEDNESDAY, Aug. 12 (HealthDay News) ... problems, according to the results of a patient survey. ... 78, who had two types of cervical neck operations ... Before the surgery, 86.4 percent of the patients reported ...
... NEW YORK, Aug. 12 Gloria Gibbons, President of Ogilvy ... have been appointed Joint Worldwide CEOs of Ogilvy Healthworld, reporting to ... In making the announcement, Mr. Young said, "Donna and Gloria ... individuals. Their joint mandate is to drive the business as ...
... ... business culture and long history of technology innovation to enhance research, development and innovation ... Scottsdale, AZ ... management and security, today announced the expansion of its global operations with the opening ...
... now the greatest threat to the health of Americans, finding an effective ... a new study in the August 2009 issue of the ... portion and calorie-controlled meal replacements used in a structured weight-loss program are ... The st u dy looked at ...
... , SWARTZ CREEK, Mich., Aug. 12 Diplomat ... 2009 Inc. 500, Inc.,s annual ranking of the fastest-growing ... at 235 in the nation is an amazing achievement, the additional details are ... Hagerman refers to are these: , , , ...
Cached Medicine News:Health News:Sisters of Charity Health System Welcomes Shannon Fogarty Jerse as Deputy General Counsel 2Health News:Sisters of Charity Health System Welcomes Shannon Fogarty Jerse as Deputy General Counsel 3Health News:Surgery for Neck Pain May Also Relieve Headaches 2Health News:Joint Worldwide CEO's of Ogilvy Healthworld Named 2Health News:Lumension Expands Global Footprint and Strengthens Capabilities with the Opening of a New Development Office in Ireland 2Health News:Lumension Expands Global Footprint and Strengthens Capabilities with the Opening of a New Development Office in Ireland 3Health News:New Published Diet Study Reveals Meal Replacements as Top Strategy for Weight Loss 2Health News:Diplomat Specialty Pharmacy Honored By Inc. Magazine As One Of The Nation's Fastest-Growing Companies 2
... V have an exceptionally sensitive plethysmograph for penile and ... Model 1061 shown below, but does not have the ... Penilab V has a Doppler. These are ready-to-use ... get started. Latex rubber cuffs do go bad ...
... When your patients come to ... want answers they can understand. Then ... RigiScan Plus Rigidity Assessment System can ... patients' penile rigidity and tumescence data...and ...
The very bright medical maginifier lamp for examination and labratory....
... were designed with the surgeon in mind. ... and value. It offers comfort and ease ... hands. The broader, anatomical design allows for ... offers sensitivity and an effective grip, wet ...
Medicine Products: